/DISREGARD RELEASE: Sino Medical Sciences Technology Inc. (SINOMED)/ 

We are advised by Sino Medical Sciences Technology Inc. (SINOMED) that journalists and other readers should disregard the news release, SINOMED® Completes Last Patient Follow-Up of the PIONEER-III Pivotal US and Japanese Trial of the BuMA Supreme® Coronary Drug-Eluting Stent, issued...

We are advised by Sino Medical Sciences Technology Inc. (SINOMED) that journalists and other readers should disregard the news release, SINOMED® Completes Last Patient Follow-Up of the PIONEER-III Pivotal US and Japanese Trial of the BuMA Supreme® Coronary Drug-Eluting Stent, issued 06-Jul-2020 over PR Newswire. The release was inadvertently issued early. A new version will be provided later today. 

 

 

Leggi anche...
I più recenti

Axplora consolida la produzione di API per fegato

EMA e AMA uniscono forze contro l’Ebola

Le Fonti Awards 25 giugno 2026: premiate a Milano le eccellenze italiane del mondo professionale e imprenditoriale

Schwazer, nuove accuse di doping: tutto sull’eritropoietina e i suoi effetti

Newsletter

Iscriviti ora per rimanere aggiornato su tutti i temi inerenti la salute.